See our products on the following page.
Aniva Pharma Hellas
Aniva Pharma Hellas is the third in row affiliate of Aniva International SA following the affiliates of Aniva Pharma Serbia and Aniva Pharma Cyprus.
Our products are used for patients with diseases such as diabetes, neurodegenerative and cerebrovascular diseases, in particular multiple sclerosis and Parkinson’s disease as well as eye diseases.
Our vision is to become a significant regional player in the broader health care sector. We will be recognized as an interactive and collaborative platform with our business partners and the community of pharmacists at large. We aim to become a pioneering brand and market-maker platform that co-develops and co-owns products with selected national and regional partners, through close ties and strategic partnerships.
A common denominator in our business is the concept of quality, covering everything from the choice of our suppliers and the raw materials that we use in our products, to the finished product on the shelf and to our business practices. And, to reach our target, we have a set of values that we apply to our business, like we do to our lives: Integrity, Openness, Flexibility, Punctuality.
Our ambition is to become a leading OTX market player in autoimmune, chronic and rare diseases market through the development, acquisition, licensing-in and exclusive representation of innovative OTX products, which provide patients and end consumers with the opportunity to address their needs, pursue a healthy lifestyle and experience a better sense of well-being.
Aniva Pharma’s corporate strategy includes the following key components:
- Promote OTX products to doctors and relevant health professionals in specific therapeutic areas.
- Constantly looking for innovative products either through its own development or collaborations with special care in safety and quality.
- Dosledna operativna izvrsnost
- Exhibit consistent operational excellence.
Aniva Pharma Hellas is the third in row affiliate of Aniva International SA ( www.aniva-int.com ) following the affiliates of Aniva Pharma Serbia and Aniva Pharma Cyprus. Aniva Pharma Hellas was established at the end of 2017 with the aim to become the first OTX company operating in the Greek health care market with a focus in neurodegenerative, chronic and rare diseases.
The company has dedicated scientific, marketing, medical and sales teams promoting a unique mix of natural biomolecular supplements for specific medical purposes all with world patents and strong clinical support, as well as food supplements of high nutritional value and uniqueness. The company is focusing in: Neurology, Ophthalmology, Diabetes and Gastroenterology. Aniva Pharma Hellas through its business collaborations and partnerships has the privilege to introduce in the Greek market forefront novel and unique products, as well as represent and co-brand well established innovative US and other European brands.
Aniva Pharma comprises a group of people with a long and successful track record: Professionals with a solid experience in Sales and Marketing in Pharma and OTC companies, in Business Development, as well as Scientists with years of research and academic excellence, while all surrounded by a team of young and talented colleagues eager to learn and unlearn in order to make things happen.
We are dedicated to building an entrepreneurial culture, where our employees feel inspired and rewarded and have the opportunity to demonstrate their skills and abilities. We foster to create an environment that offers our people the experiences and the means to reach their full potential.
Eyeaspis Dry Eye is a unique formulated dietary supplement based on years of research to provide relief for occasional dryness, redness, scratchiness and irritation in the eye. The Number 1 dietary supplement in America.
Eyeaspis Re-D is a specially formulated food supplement to delay the onset and slow the progression to Diabetic Retinopathy. It addresses the eye health needs of people with diabetes at risk…
NEUROASPIS® plp10 is a produce of more than 10 years of research and clinical development, where the Clinical Study Phase II is finished and published in 2013 in BMJ, while the Clinical Trial of Phase III with 220 patients is under way.
Glucoaspis – COMING SOON
Glucoaspis is a unique blend of well documented well-known and new naturally derived substances, specially formulated and manufactured in a unique galenic form of modified release pallets.